#United States #New York #Pomerantz Law #Sangamo Therapeutics #SGMO

Investigation of Sangamo Therapeutics: A Call to Investors

Pomerantz Law Firm, a well-regarded entity specialized in corporate and securities litigation, has launched an investigation on behalf of investors of Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This investigation aims to determine whether the Company and its executives may have engaged in unlawful business practices or securities fraud.

On December 30, 2024, just after the markets closed, Sangamo made public an unexpected announcement regarding its partnership with Pfizer concerning the hemophilia A gene therapy candidate, giroctocogene fitelparvovec. The news stated that Pfizer would relinquish its rights for development and commercialization for this promising product, deciding not to pursue its commercialization so close to critical submission timelines for regulatory approval. Sangamo expressed surprise and disappointment over Pfizer's decision, which they believed would impact the anticipated Biologics License Application and Marketing Authorisation Application submissions they were preparing for early 2025.

The implications of this decision were immediate and severe, leading to a notable decline in Sangamo's stock price in the following market day, the reaction highlighting investor worry over the future of a key product that was nearing its final development stages. The termination of the collaboration with Pfizer will take effect on April 21, 2025, at which point Sangamo will regain full control over the giroctocogene fitelparvovec program.

Pomerantz LLP, known for its long-standing commitment to advocating for investors' rights, emphasizes that firm has historically achieved substantial recoveries for victims of corporate misconduct. Their founder, Abraham L. Pomerantz, was pivotal in defining modern class action practices. Today, the firm stands at the forefront of addressing allegations related to securities fraud and violations of fiduciary duty.

Investors who believe they may have experienced losses due to Sangamo's latest operations are advised to contact Pomerantz for guidance and potential participation in the ongoing investigation. Danielle Peyton, a representative of Pomerantz, is available to discuss the claims, and interested parties can reach her at [email protected] or via phone at 646-581-9980, ext. 7980.

While the current situation certainly raises questions regarding Sangamo's leadership and direction, both current and prospective investors are urged to remain vigilant. Developments in clinical advancements, corporate collaborations, and financial stability will be crucial aspects to monitor in the coming months, especially in light of the impending transition back to Sangamo's oversight of pivotal gene therapy development.

As the investigation unfolds, those with financial stakes in Sangamo Therapeutics will seek clarity on whether the actions of its executives constitute breaches of trust or represent unforeseen business risks. Continued updates from Pomerantz and further announcements from Sangamo will likely shape the narrative around this significant biotechnology firm. Ensuring compliance with regulatory standards will also remain central to their progress as they navigate through this turbulent phase.

In conclusion, investors of Sangamo Therapeutics should actively follow the situation and consult legal expertise when necessary. Pomerantz Law Firm's commitment to providing assistance during this investigation could potentially lead to significant reparations for those impacted by the recent developments at Sangamo Therapeutics.